APO Research
Talk to an analyst

APO RESEARCH · REPORT

C-MET & HGF Inhibitors

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Selected research

Market Analysis & Forecast

Global C-MET & HGF Inhibitors Market Analysis and Forecast 2026-2032

28 December 2025209 pages

Choose your research edition.

Industry ResearchC-MET & HGF Inhibitors Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal C-MET & HGF Inhibitors Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal C-MET & HGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C-MET & HGF Inhibitors Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal C-MET & HGF Inhibitors Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.

C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.

Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.

This report presents an overview of global market for C-MET & HGF Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of C-MET & HGF Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for C-MET & HGF Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the C-MET & HGF Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global C-MET & HGF Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for C-MET & HGF Inhibitors sales, projected growth trends, production technology, application and end-user industry.

C-MET & HGF Inhibitors Segment by Company

Exelixis

Ipsen

Pfizer

Novartis

Takeda

Merck KGaA

Merck

Daiichi Sankyo

GSK

Bristol-Myers Squibb(BMS)

Roche

AVEO Pharmaceuticals

Amgen

AstraZeneca

Mirati Therapeutics

Eli Lilly

Johnson & Johnson

Eisai

Hutchison MediPharma

Kringle Pharmaceuticals

C-MET & HGF Inhibitors Segment by Type

Cabozantinib

Crizotinib

Others

C-MET & HGF Inhibitors Segment by Application

Hospital

Drug Store

C-MET & HGF Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-MET & HGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C-MET & HGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-MET & HGF Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of C-MET & HGF Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, C-MET & HGF Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global C-MET & HGF Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cabozantinib Major Manufacturers Table 3. Crizotinib Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global C-MET & HGF Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Manufacturers Table 7. Drug Store Major Manufacturers Table 8. C-MET & HGF Inhibitors Industry Trends Table 9. C-MET & HGF Inhibitors Industry Drivers Table 10. C-MET & HGF Inhibitors Industry Opportunities and Challenges Table 11. C-MET & HGF Inhibitors Industry Restraints Table 12. Global C-MET & HGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global C-MET & HGF Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 14. Global C-MET & HGF Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 15. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2021-2026) Table 16. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2027-2032) Table 17. Global C-MET & HGF Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global C-MET & HGF Inhibitors Sales by Region (2021-2026) & (K Units) Table 19. Global C-MET & HGF Inhibitors Sales by Region (2027-2032) & (K Units) Table 20. Global C-MET & HGF Inhibitors Sales Market Share by Region (2021-2026) Table 21. Global C-MET & HGF Inhibitors Sales Market Share by Region (2027-2032) Table 22. Global C-MET & HGF Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global C-MET & HGF Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 24. Global C-MET & HGF Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 26. Global C-MET & HGF Inhibitors Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global C-MET & HGF Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global C-MET & HGF Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global C-MET & HGF Inhibitors Manufacturers, Product Type & Application Table 30. Global C-MET & HGF Inhibitors Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global C-MET & HGF Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global C-MET & HGF Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 35. Global C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 36. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2026) Table 37. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2027-2032) Table 38. Global C-MET & HGF Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 40. Global C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 41. Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2026) Table 42. Global C-MET & HGF Inhibitors Sales Market Share by Type (2027-2032) Table 43. Global C-MET & HGF Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 44. Global C-MET & HGF Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 45. Global C-MET & HGF Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 47. Global C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 48. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2026) Table 49. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2027-2032) Table 50. Global C-MET & HGF Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 52. Global C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 53. Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2026) Table 54. Global C-MET & HGF Inhibitors Sales Market Share by Application (2027-2032) Table 55. Global C-MET & HGF Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 56. Global C-MET & HGF Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 57. Exelixis Company Information Table 58. Exelixis Business Overview Table 59. Exelixis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Exelixis C-MET & HGF Inhibitors Product Portfolio Table 61. Exelixis Recent Development Table 62. Ipsen Company Information Table 63. Ipsen Business Overview Table 64. Ipsen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Ipsen C-MET & HGF Inhibitors Product Portfolio Table 66. Ipsen Recent Development Table 67. Pfizer Company Information Table 68. Pfizer Business Overview Table 69. Pfizer C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Pfizer C-MET & HGF Inhibitors Product Portfolio Table 71. Pfizer Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Novartis C-MET & HGF Inhibitors Product Portfolio Table 76. Novartis Recent Development Table 77. Takeda Company Information Table 78. Takeda Business Overview Table 79. Takeda C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Takeda C-MET & HGF Inhibitors Product Portfolio Table 81. Takeda Recent Development Table 82. Merck KGaA Company Information Table 83. Merck KGaA Business Overview Table 84. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Merck KGaA C-MET & HGF Inhibitors Product Portfolio Table 86. Merck KGaA Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Merck C-MET & HGF Inhibitors Product Portfolio Table 91. Merck Recent Development Table 92. Daiichi Sankyo Company Information Table 93. Daiichi Sankyo Business Overview Table 94. Daiichi Sankyo C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio Table 96. Daiichi Sankyo Recent Development Table 97. GSK Company Information Table 98. GSK Business Overview Table 99. GSK C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. GSK C-MET & HGF Inhibitors Product Portfolio Table 101. GSK Recent Development Table 102. Bristol-Myers Squibb(BMS) Company Information Table 103. Bristol-Myers Squibb(BMS) Business Overview Table 104. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio Table 106. Bristol-Myers Squibb(BMS) Recent Development Table 107. Roche Company Information Table 108. Roche Business Overview Table 109. Roche C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Roche C-MET & HGF Inhibitors Product Portfolio Table 111. Roche Recent Development Table 112. AVEO Pharmaceuticals Company Information Table 113. AVEO Pharmaceuticals Business Overview Table 114. AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 116. AVEO Pharmaceuticals Recent Development Table 117. Amgen Company Information Table 118. Amgen Business Overview Table 119. Amgen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Amgen C-MET & HGF Inhibitors Product Portfolio Table 121. Amgen Recent Development Table 122. AstraZeneca Company Information Table 123. AstraZeneca Business Overview Table 124. AstraZeneca C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. AstraZeneca C-MET & HGF Inhibitors Product Portfolio Table 126. AstraZeneca Recent Development Table 127. Mirati Therapeutics Company Information Table 128. Mirati Therapeutics Business Overview Table 129. Mirati Therapeutics C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio Table 131. Mirati Therapeutics Recent Development Table 132. Eli Lilly Company Information Table 133. Eli Lilly Business Overview Table 134. Eli Lilly C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Eli Lilly C-MET & HGF Inhibitors Product Portfolio Table 136. Eli Lilly Recent Development Table 137. Johnson & Johnson Company Information Table 138. Johnson & Johnson Business Overview Table 139. Johnson & Johnson C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio Table 141. Johnson & Johnson Recent Development Table 142. Eisai Company Information Table 143. Eisai Business Overview Table 144. Eisai C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Eisai C-MET & HGF Inhibitors Product Portfolio Table 146. Eisai Recent Development Table 147. Hutchison MediPharma Company Information Table 148. Hutchison MediPharma Business Overview Table 149. Hutchison MediPharma C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio Table 151. Hutchison MediPharma Recent Development Table 152. Kringle Pharmaceuticals Company Information Table 153. Kringle Pharmaceuticals Business Overview Table 154. Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 156. Kringle Pharmaceuticals Recent Development Table 157. North America C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 158. North America C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 159. North America C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 160. North America C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 161. North America C-MET & HGF Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 162. North America C-MET & HGF Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 163. North America C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 164. North America C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 165. North America C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 166. North America C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 167. North America C-MET & HGF Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 168. North America C-MET & HGF Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 169. North America C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. North America C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. North America C-MET & HGF Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. North America C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 173. North America C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 174. North America C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 175. North America C-MET & HGF Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 176. North America C-MET & HGF Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 177. United States C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 178. Canada C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 179. Mexico C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 180. Europe C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 181. Europe C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 182. Europe C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 183. Europe C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 184. Europe C-MET & HGF Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 185. Europe C-MET & HGF Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 186. Europe C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 187. Europe C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 188. Europe C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 189. Europe C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 190. Europe C-MET & HGF Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 191. Europe C-MET & HGF Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 192. Europe C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 193. Europe C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 194. Europe C-MET & HGF Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 195. Europe C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 196. Europe C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 197. Europe C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 198. Europe C-MET & HGF Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 199. Europe C-MET & HGF Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 200. Germany C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 201. France C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 202. U.K. C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 203. Italy C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 204. Russia C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 205. Spain C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 206. Netherlands C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 207. Switzerland C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 208. Sweden C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 209. Poland C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 210. China C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 211. China C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 212. China C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 213. China C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 214. China C-MET & HGF Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 215. China C-MET & HGF Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 216. China C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 217. China C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 218. China C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 219. China C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 220. China C-MET & HGF Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 221. China C-MET & HGF Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 222. Asia C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 223. Asia C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 224. Asia C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 225. Asia C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 226. Asia C-MET & HGF Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 227. Asia C-MET & HGF Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 228. Asia C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 229. Asia C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 230. Asia C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 231. Asia C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 232. Asia C-MET & HGF Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 233. Asia C-MET & HGF Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 234. Asia C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 235. Asia C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 236. Asia C-MET & HGF Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 237. Asia C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 238. Asia C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 239. Asia C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 240. Asia C-MET & HGF Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 241. Asia C-MET & HGF Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 242. Japan C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 243. South Korea C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 244. India C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 245. Australia C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 246. Taiwan C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 247. Southeast Asia C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 248. SAMEA C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 249. SAMEA C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 250. SAMEA C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 251. SAMEA C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 252. SAMEA C-MET & HGF Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 253. SAMEA C-MET & HGF Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 254. SAMEA C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 255. SAMEA C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 256. SAMEA C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 257. SAMEA C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 258. SAMEA C-MET & HGF Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 259. SAMEA C-MET & HGF Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 260. SAMEA C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 261. SAMEA C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 262. SAMEA C-MET & HGF Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 263. SAMEA C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 264. SAMEA C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 265. SAMEA C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 266. SAMEA C-MET & HGF Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 267. SAMEA C-MET & HGF Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 268. Brazil C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 269. Argentina C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 270. Chile C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 271. Colombia C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 272. Peru C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 273. Saudi Arabia C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 274. Israel C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 275. UAE C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 276. Turkey C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 277. Iran C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 278. Egypt C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Table 279. Key Raw Materials Table 280. Raw Materials Key Suppliers Table 281. C-MET & HGF Inhibitors Distributors List Table 282. C-MET & HGF Inhibitors Customers List Table 283. Research Programs/Design for This Report Table 284. Authors List of This Report Table 285. Secondary Sources Table 286. Primary Sources List of Figures Figure 1. C-MET & HGF Inhibitors Image Figure 2. Global C-MET & HGF Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global C-MET & HGF Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cabozantinib Image Figure 5. Crizotinib Image Figure 6. Others Image Figure 7. Global C-MET & HGF Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global C-MET & HGF Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Drug Store Image Figure 11. Global C-MET & HGF Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 13. Global C-MET & HGF Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global C-MET & HGF Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2021-2032) Figure 16. Global C-MET & HGF Inhibitors Sales (2021-2032) & (K Units) Figure 17. Global C-MET & HGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global C-MET & HGF Inhibitors Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico C-MET & HGF Inhibitors Sales YoY (2021-2032) & (K Units) Figure 20. Europe C-MET & HGF Inhibitors Sales YoY (2021-2032) & (K Units) Figure 21. China C-MET & HGF Inhibitors Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) C-MET & HGF Inhibitors Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa C-MET & HGF Inhibitors Sales YoY (2021-2032) & (K Units) Figure 24. Global C-MET & HGF Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global C-MET & HGF Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global C-MET & HGF Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global C-MET & HGF Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2032) Figure 30. Global C-MET & HGF Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global C-MET & HGF Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2032) Figure 33. Global C-MET & HGF Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global C-MET & HGF Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2032) Figure 36. Global C-MET & HGF Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global C-MET & HGF Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2032) Figure 39. North America C-MET & HGF Inhibitors Revenue Share by Type (2021-2032) Figure 40. North America C-MET & HGF Inhibitors Sales Share by Type (2021-2032) Figure 41. North America C-MET & HGF Inhibitors Revenue Share by Application (2021-2032) Figure 42. North America C-MET & HGF Inhibitors Sales Share by Application (2021-2032) Figure 43. North America C-MET & HGF Inhibitors Revenue Share by Country (2021-2032) Figure 44. North America C-MET & HGF Inhibitors Sales Share by Country (2021-2032) Figure 45. Europe C-MET & HGF Inhibitors Revenue Share by Type (2021-2032) Figure 46. Europe C-MET & HGF Inhibitors Sales Share by Type (2021-2032) Figure 47. Europe C-MET & HGF Inhibitors Revenue Share by Application (2021-2032) Figure 48. Europe C-MET & HGF Inhibitors Sales Share by Application (2021-2032) Figure 49. Europe C-MET & HGF Inhibitors Revenue Share by Country (2021-2032) Figure 50. Europe C-MET & HGF Inhibitors Sales Share by Country (2021-2032) Figure 51. China C-MET & HGF Inhibitors Revenue Share by Type (2021-2032) Figure 52. China C-MET & HGF Inhibitors Sales Share by Type (2021-2032) Figure 53. China C-MET & HGF Inhibitors Revenue Share by Application (2021-2032) Figure 54. China C-MET & HGF Inhibitors Sales Share by Application (2021-2032) Figure 55. Asia C-MET & HGF Inhibitors Revenue Share by Type (2021-2032) Figure 56. Asia C-MET & HGF Inhibitors Sales Share by Type (2021-2032) Figure 57. Asia C-MET & HGF Inhibitors Revenue Share by Application (2021-2032) Figure 58. Asia C-MET & HGF Inhibitors Sales Share by Application (2021-2032) Figure 59. Asia C-MET & HGF Inhibitors Revenue Share by Country (2021-2032) Figure 60. Asia C-MET & HGF Inhibitors Sales Share by Country (2021-2032) Figure 61. SAMEA C-MET & HGF Inhibitors Revenue Share by Type (2021-2032) Figure 62. SAMEA C-MET & HGF Inhibitors Sales Share by Type (2021-2032) Figure 63. SAMEA C-MET & HGF Inhibitors Revenue Share by Application (2021-2032) Figure 64. SAMEA C-MET & HGF Inhibitors Sales Share by Application (2021-2032) Figure 65. SAMEA C-MET & HGF Inhibitors Revenue Share by Country (2021-2032) Figure 66. SAMEA C-MET & HGF Inhibitors Sales Share by Country (2021-2032) Figure 67. C-MET & HGF Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. C-MET & HGF Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Cabozantinib
  • Crizotinib
  • Others
Applications
  • Hospital
  • Drug Store
Companies covered
  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Merck
  • Daiichi Sankyo
  • GSK
  • Bristol-Myers Squibb(BMS)
  • Roche
  • AVEO Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Mirati Therapeutics
  • Eli Lilly
  • Johnson & Johnson
  • Eisai
  • Hutchison MediPharma
  • Kringle Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 C-MET & HGF Inhibitors Market by Type
  3. 1.2.1 Global C-MET & HGF Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cabozantinib
  5. 1.2.3 Crizotinib
  6. 1.2.4 Others
  7. 1.3 C-MET & HGF Inhibitors Market by Application
  8. 1.3.1 Global C-MET & HGF Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Drug Store
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 C-MET & HGF Inhibitors Market Dynamics
  1. 2.1 C-MET & HGF Inhibitors Industry Trends
  2. 2.2 C-MET & HGF Inhibitors Industry Drivers
  3. 2.3 C-MET & HGF Inhibitors Industry Opportunities and Challenges
  4. 2.4 C-MET & HGF Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global C-MET & HGF Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global C-MET & HGF Inhibitors Revenue by Region
  3. 3.2.1 Global C-MET & HGF Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global C-MET & HGF Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global C-MET & HGF Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global C-MET & HGF Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global C-MET & HGF Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global C-MET & HGF Inhibitors Sales by Region
  9. 3.4.1 Global C-MET & HGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global C-MET & HGF Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global C-MET & HGF Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global C-MET & HGF Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global C-MET & HGF Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global C-MET & HGF Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global C-MET & HGF Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global C-MET & HGF Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global C-MET & HGF Inhibitors Sales by Manufacturers
  6. 4.2.1 Global C-MET & HGF Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global C-MET & HGF Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global C-MET & HGF Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global C-MET & HGF Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global C-MET & HGF Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global C-MET & HGF Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global C-MET & HGF Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global C-MET & HGF Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 C-MET & HGF Inhibitors Tier 1, Tier 2, and Tier 3
5 C-MET & HGF Inhibitors Market by Type
  1. 5.1 Global C-MET & HGF Inhibitors Revenue by Type
  2. 5.1.1 Global C-MET & HGF Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global C-MET & HGF Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global C-MET & HGF Inhibitors Sales by Type
  6. 5.2.1 Global C-MET & HGF Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global C-MET & HGF Inhibitors Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global C-MET & HGF Inhibitors Price by Type
6 C-MET & HGF Inhibitors Market by Application
  1. 6.1 Global C-MET & HGF Inhibitors Revenue by Application
  2. 6.1.1 Global C-MET & HGF Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global C-MET & HGF Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global C-MET & HGF Inhibitors Sales by Application
  6. 6.2.1 Global C-MET & HGF Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global C-MET & HGF Inhibitors Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global C-MET & HGF Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Exelixis
  2. 7.1.1 Exelixis Company Information
  3. 7.1.2 Exelixis Business Overview
  4. 7.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio
  6. 7.1.5 Exelixis Recent Developments
  7. 7.2 Ipsen
  8. 7.2.1 Ipsen Company Information
  9. 7.2.2 Ipsen Business Overview
  10. 7.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio
  12. 7.2.5 Ipsen Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Takeda
  26. 7.5.1 Takeda Company Information
  27. 7.5.2 Takeda Business Overview
  28. 7.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio
  30. 7.5.5 Takeda Recent Developments
  31. 7.6 Merck KGaA
  32. 7.6.1 Merck KGaA Company Information
  33. 7.6.2 Merck KGaA Business Overview
  34. 7.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio
  36. 7.6.5 Merck KGaA Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Merck C-MET & HGF Inhibitors Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 GSK
  50. 7.9.1 GSK Company Information
  51. 7.9.2 GSK Business Overview
  52. 7.9.3 GSK C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 GSK C-MET & HGF Inhibitors Product Portfolio
  54. 7.9.5 GSK Recent Developments
  55. 7.10 Bristol-Myers Squibb(BMS)
  56. 7.10.1 Bristol-Myers Squibb(BMS) Company Information
  57. 7.10.2 Bristol-Myers Squibb(BMS) Business Overview
  58. 7.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio
  60. 7.10.5 Bristol-Myers Squibb(BMS) Recent Developments
  61. 7.11 Roche
  62. 7.11.1 Roche Company Information
  63. 7.11.2 Roche Business Overview
  64. 7.11.3 Roche C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Roche C-MET & HGF Inhibitors Product Portfolio
  66. 7.11.5 Roche Recent Developments
  67. 7.12 AVEO Pharmaceuticals
  68. 7.12.1 AVEO Pharmaceuticals Company Information
  69. 7.12.2 AVEO Pharmaceuticals Business Overview
  70. 7.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  72. 7.12.5 AVEO Pharmaceuticals Recent Developments
  73. 7.13 Amgen
  74. 7.13.1 Amgen Company Information
  75. 7.13.2 Amgen Business Overview
  76. 7.13.3 Amgen C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Amgen C-MET & HGF Inhibitors Product Portfolio
  78. 7.13.5 Amgen Recent Developments
  79. 7.14 AstraZeneca
  80. 7.14.1 AstraZeneca Company Information
  81. 7.14.2 AstraZeneca Business Overview
  82. 7.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca C-MET & HGF Inhibitors Product Portfolio
  84. 7.14.5 AstraZeneca Recent Developments
  85. 7.15 Mirati Therapeutics
  86. 7.15.1 Mirati Therapeutics Company Information
  87. 7.15.2 Mirati Therapeutics Business Overview
  88. 7.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio
  90. 7.15.5 Mirati Therapeutics Recent Developments
  91. 7.16 Eli Lilly
  92. 7.16.1 Eli Lilly Company Information
  93. 7.16.2 Eli Lilly Business Overview
  94. 7.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Eli Lilly C-MET & HGF Inhibitors Product Portfolio
  96. 7.16.5 Eli Lilly Recent Developments
  97. 7.17 Johnson & Johnson
  98. 7.17.1 Johnson & Johnson Company Information
  99. 7.17.2 Johnson & Johnson Business Overview
  100. 7.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio
  102. 7.17.5 Johnson & Johnson Recent Developments
  103. 7.18 Eisai
  104. 7.18.1 Eisai Company Information
  105. 7.18.2 Eisai Business Overview
  106. 7.18.3 Eisai C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Eisai C-MET & HGF Inhibitors Product Portfolio
  108. 7.18.5 Eisai Recent Developments
  109. 7.19 Hutchison MediPharma
  110. 7.19.1 Hutchison MediPharma Company Information
  111. 7.19.2 Hutchison MediPharma Business Overview
  112. 7.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio
  114. 7.19.5 Hutchison MediPharma Recent Developments
  115. 7.20 Kringle Pharmaceuticals
  116. 7.20.1 Kringle Pharmaceuticals Company Information
  117. 7.20.2 Kringle Pharmaceuticals Business Overview
  118. 7.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  120. 7.20.5 Kringle Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America C-MET & HGF Inhibitors Market Size by Type
  2. 8.1.1 North America C-MET & HGF Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America C-MET & HGF Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America C-MET & HGF Inhibitors Price by Type (2021-2032)
  5. 8.2 North America C-MET & HGF Inhibitors Market Size by Application
  6. 8.2.1 North America C-MET & HGF Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America C-MET & HGF Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America C-MET & HGF Inhibitors Price by Application (2021-2032)
  9. 8.3 North America C-MET & HGF Inhibitors Market Size by Country
  10. 8.3.1 North America C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America C-MET & HGF Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe C-MET & HGF Inhibitors Market Size by Type
  2. 9.1.1 Europe C-MET & HGF Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe C-MET & HGF Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe C-MET & HGF Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe C-MET & HGF Inhibitors Market Size by Application
  6. 9.2.1 Europe C-MET & HGF Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe C-MET & HGF Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe C-MET & HGF Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe C-MET & HGF Inhibitors Market Size by Country
  10. 9.3.1 Europe C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe C-MET & HGF Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China C-MET & HGF Inhibitors Market Size by Type
  2. 10.1.1 China C-MET & HGF Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China C-MET & HGF Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China C-MET & HGF Inhibitors Price by Type (2021-2032)
  5. 10.2 China C-MET & HGF Inhibitors Market Size by Application
  6. 10.2.1 China C-MET & HGF Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China C-MET & HGF Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China C-MET & HGF Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia C-MET & HGF Inhibitors Market Size by Type
  2. 11.1.1 Asia C-MET & HGF Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia C-MET & HGF Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia C-MET & HGF Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia C-MET & HGF Inhibitors Market Size by Application
  6. 11.2.1 Asia C-MET & HGF Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia C-MET & HGF Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia C-MET & HGF Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia C-MET & HGF Inhibitors Market Size by Country
  10. 11.3.1 Asia C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia C-MET & HGF Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA C-MET & HGF Inhibitors Market Size by Type
  2. 12.1.1 SAMEA C-MET & HGF Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA C-MET & HGF Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA C-MET & HGF Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA C-MET & HGF Inhibitors Market Size by Application
  6. 12.2.1 SAMEA C-MET & HGF Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA C-MET & HGF Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA C-MET & HGF Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA C-MET & HGF Inhibitors Market Size by Country
  10. 12.3.1 SAMEA C-MET & HGF Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA C-MET & HGF Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA C-MET & HGF Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 C-MET & HGF Inhibitors Value Chain Analysis
  2. 13.1.1 C-MET & HGF Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 C-MET & HGF Inhibitors Production Mode & Process
  6. 13.2 C-MET & HGF Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 C-MET & HGF Inhibitors Distributors
  9. 13.2.3 C-MET & HGF Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst